Congressional Inquiry into Eli Lilly's Clinical Research Operations within the People's Republic of China
美國國會就禮來製藥在中國的臨床研究營運進行調查
Introduction
The House Select Committee on the Chinese Communist Party has initiated a formal investigation into the clinical trial activities of Eli Lilly and Company in China.
美國眾議院中國共產黨特設委員會已正式對禮來製藥（Eli Lilly and Company）在中國的臨床試驗活動展開調查。
Main Body
The inquiry, led by Chairman John Moolenaar, focuses on the potential intersection of private pharmaceutical research and Chinese state security interests. Specifically, the Committee has requested documentation regarding clinical trials conducted at facilities affiliated with the People's Liberation Army (PLA) and within the Xinjiang region. Public records indicate that since 2003, Eli Lilly has collaborated on over 220 studies in China, including 16 involving military medical centers and 11 in Xinjiang. The Committee posits that such collaborations may facilitate the unauthorized transfer of proprietary biotechnology and intellectual property to the Chinese military, thereby compromising U.S. national security and economic competitiveness.
此次調查由主席 John Moolenaar 領導，重點關注私人製藥研究與中國國家安全利益之間潛在的交集。具體而言，委員會已要求提供關於在中國人民解放軍（PLA）附屬機構以及新疆地區進行的臨床試驗文件。公開記錄顯示，自 2003 年起，禮來製藥在中國合作了超過 220 項研究，其中包括 16 項涉及軍方醫療中心以及 11 項在新疆進行。委員會認為，此類合作可能會促使專有生物技術與知識產權在未經授權的情況下轉移至中國軍方，從而損害美國的國家安全與經濟競爭力。
Furthermore, the investigation addresses ethical concerns regarding participant autonomy and informed consent. The Committee cites reports from the United Nations and the U.S. State Department alleging systemic human rights abuses in Xinjiang, suggesting that the environment may preclude the possibility of voluntary participation in medical trials. Additionally, the inquiry examines whether the rapid expansion of China's clinical trial infrastructure—driven by state subsidies and regulatory shifts—has compromised ethical standards. These concerns coincide with Eli Lilly's increased capital commitment to the region, including a $3 billion manufacturing expansion and multi-billion dollar research partnerships with Innovent Biologics and Haisco Pharmaceutical Group.
此外，調查還涉及參與者自主權與知情同意的倫理疑慮。委員會引用聯合國與美國國務院的報告，指控新疆存在系統性人權侵害，暗示該環境可能排除醫療試驗自願參與的可能性。此外，調查還在研究中國在國家補貼與監管轉型驅動下，臨床試驗基礎設施的快速擴張是否損害了倫理標準。這些憂慮與禮來製藥增加對該地區的資本投入相吻合，包括 30 億美元的製造擴張，以及與信達生物（Innovent Biologics）和海思可藥業（Haisco Pharmaceutical Group）價值數十億美元的研究合作夥伴關係。
Conclusion
Eli Lilly has acknowledged receipt of the inquiry and is currently reviewing the request for documentation, which is due by July 17.
禮來製藥已確認收到調查要求，目前正在審閱相關文件請求，該文件需於 7 月 17 日前提交。
Vocabulary Learning
The Architecture of Formal Speculation
To move from B2 to C2, a student must transition from stating facts to constructing nuanced hypotheses. The provided text is a masterclass in Hedging and Epistemic Modality—the art of suggesting a possibility without claiming absolute certainty, which is essential for high-level diplomatic, legal, and academic writing.
◈ The 'Nuance Pivot': From Certainty to Possibility
Notice the shift from the concrete (the existence of trials) to the speculative (the risk of espionage). The author avoids saying "The trials leaked data," which would be a legal liability. Instead, they use:
*"...collaborations may facilitate the unauthorized transfer..."
C2 Linguistic Breakdown:
- May facilitate: This isn't just a modal of possibility; it is a strategic buffer. It frames the risk as a logical consequence rather than a proven event.
- Preclude the possibility of: Instead of saying "participants cannot consent," the text uses a double-negative structure (preclude + possibility). This creates a formal distance, suggesting that the environment makes the action impossible, rather than claiming a specific instance of coercion.
◈ Lexical Precision: High-Density Nominals
C2 English is characterized by 'nominalization'—turning complex processes into single noun phrases to increase information density. Compare these two levels:
- B2 Approach: China is spending a lot of money to make clinical trials grow faster, and this might make ethical standards lower.
- C2 Approach (The Text): *"...the rapid expansion of China's clinical trial infrastructure—driven by state subsidies and regulatory shifts—has compromised ethical standards."
Analysis of the 'C2' upgrade:
- "Rapid expansion of... infrastructure": Replaces the verb "grow" with a conceptual noun phrase.
- "Driven by state subsidies": An appositive phrase that provides causality without needing a new sentence.
- "Regulatory shifts": A precise term for changes in law, replacing the vague "changes in rules."
◈ Sophisticated Collocations for the C2 Portfolio
Integrate these pairings into your writing to signal mastery:
- : (Specific ownership of scientific secrets)
- : (Indicating the problem is built into the system, not accidental)
- : (A formal way to describe financial investment)
- : (Establishing the official nature of the process)